Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,173 questions in 89 reviews · Neuromuscular
current versionsNo studies 302 · 25.7%Ungraded 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
A functional programme vs a stretching programme Quality of life (SF‐36 PCS) · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | 1 study · 49 participants | Low |
A functional programme vs a stretching programme Quality of life (SF‐36 MCS) · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | 1 study · 49 participants | Low |
A functional programme vs a stretching programme Adverse events/serious adverse events · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | NR | No studies |
A physical activity programme (weight‐bearing) vs no physical activity programme Time spent walking (minutes per week, activity monitor) · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | 1 study · 74 participants | Low |
A physical activity programme (weight‐bearing) vs no physical activity programme Time spent walking (minutes per week, activity monitor) · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | 1 study · 70 participants | Low |
A physical activity programme (weight‐bearing) vs no physical activity programme Quality of life · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | NR | No studies |
A physical activity programme (weight‐bearing) vs no physical activity programme Adverse events/serious adverse events · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | NR | No studies |
A sensor‐based, interactive exercise programme vs no sensor‐based, interactive exercise programme Time spent walking (hours per 48 hours, activity monitor) · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | 1 study · 25 participants | Very low |
A sensor‐based, interactive exercise programme vs no sensor‐based, interactive exercise programme Quality of life (SF‐12 PCS) · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | 1 study · 35 participants | Very low |
A sensor‐based, interactive exercise programme vs no sensor‐based, interactive exercise programme Quality of life (SF‐12 MCS) · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | 1 study · 35 participants | Low |
A sensor‐based, interactive exercise programme vs no sensor‐based, interactive exercise programme Adverse events/serious adverse events · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Idebenone vs placebo Change in respiratory function from baseline to 12 months, assessed by forced vital capacity (FVC) Assessed by: change from baseline in per cent of predicted values. · people with Duchenne muscular dystrophy and progressive respiratory decline Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive… (2021) · Cochrane | no estimate extracted | 1 study · 64 participants | Low |
Idebenone vs placebo Hospitalisation due to respiratory infection · people with Duchenne muscular dystrophy and progressive respiratory decline Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive… (2021) · Cochrane | no estimate extracted | NR | No studies |
Idebenone vs placebo Quality of life Assessed by: Pediatric Quality of Life Inventory, change from baseline (0 to 100; 0 = worst outcome, 100 = best outcome) · people with Duchenne muscular dystrophy and progressive respiratory decline Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive… (2021) · Cochrane | no estimate extracted | 1 study · 63 participants | Moderate |
Idebenone vs placebo Serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive… (2021) · Cochrane | RR 0.42 [0.09, 2.04] | 1 study · 66 participants | Low |
Idebenone vs placebo Non‐serious adverse events · people with Duchenne muscular dystrophy and progressive respiratory decline Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive… (2021) · Cochrane | RR 1 [0.88, 1.13] | 1 study · 66 participants | Low |
Oral creatine vs placebo Change in disability score · children with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 40 participants | Moderate |
Oral gabapentin vs placebo Acquiring ability to walk · adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 73 participants | Low |
Oral gabapentin vs placebo Change in quality of life · adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 67 participants | Low |
Oral gabapentin vs placebo Change in pulmonary function · adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 65 participants | Low |
Oral gabapentin vs placebo Time from beginning of treatment to death or full‐time ventilation · adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 84 participants | Moderate |
Oral gabapentin vs placebo Adverse events related to treatment · adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 65 participants | Low |
Oral hydroxyurea vs placebo Change in disability score · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 57 participants | Low |
Oral hydroxyurea vs placebo Change in disability score · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 38 participants | Moderate |
Oral hydroxyurea vs placebo Change in muscle strength · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 57 participants | Moderate |
Oral hydroxyurea vs placebo Acquiring the ability to stand or walk · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral hydroxyurea vs placebo Change in quality of life · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral creatine vs placebo Change in total muscle strength (total muscle strength) · children with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 22 participants | Low |
Oral hydroxyurea vs placebo Change in pulmonary function · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 57 participants | Low |
Oral hydroxyurea vs placebo Time from beginning of treatment until death or full‐time ventilation · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 57 participants | Moderate |
Oral hydroxyurea vs placebo Adverse events related to treatment · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 57 participants | Moderate |
Intrathecal injected nusinersen vs sham procedure Change in disability score · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | MD 5.9 [3.7, 8.1] | 1 study · 126 participants | Moderate |
Intrathecal injected nusinersen vs sham procedure Change in disability score (3 point‐change) · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | RR 1.8 [0.99, 3.1] | 1 study · 126 participants | Moderate |
Intrathecal injected nusinersen vs sham procedure Change in muscle strength · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intrathecal injected nusinersen vs sham procedure Acquiring the ability to stand or walk · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | RR 0.5 [0.03, 7.8] | 1 study · 126 participants | Low |
Intrathecal injected nusinersen vs sham procedure Change in quality of life · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intrathecal injected nusinersen vs sham procedure Change in pulmonary function · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intrathecal injected nusinersen vs sham procedure Time from beginning of treatment until death or full‐time ventilation · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral creatine vs placebo Acquiring the ability to stand or walk · children with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intrathecal injected nusinersen vs sham procedure Adverse events related to treatment · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | RR 0.9 [0.9, 1] | 1 study · 126 participants | Moderate |
Oral olesoxime vs placebo Change in disability score · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 160 participants | Very low |
Oral olesoxime vs placebo Change in disability score · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 160 participants | Very low |
Oral olesoxime vs placebo Change in disability score · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | RR 1.43 | 1 study · 160 participants | Very low |
Oral olesoxime vs placebo Change in disability score · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 160 participants | Low |
Oral olesoxime vs placebo Change in muscle strength · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral olesoxime vs placebo Acquiring the ability to stand or walk · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral olesoxime vs placebo Change in quality of life · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 108 participants | Low |
Oral olesoxime vs placebo Change in pulmonary function · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 102 participants | Low |
Oral olesoxime vs placebo Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 160 participants | Moderate |
Oral creatine vs placebo Change in quality of life · children with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | 1 study · 38 participants | Low |